Navigation Links
Prometheus Launches ProOnc Dx Cancer Diagnostics

SAN DIEGO, Oct. 15 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

"Prometheus has a long and successful history of providing innovative diagnostics that complement targeted therapeutics to help physicians individualize patient care," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "Now we are proud to introduce the first three products from our cancer diagnostics portfolio with the launch of ProOnc Dx. We believe that these highly tissue-specific tests provide more objective and quantitative results than current methods, which, may lead to more personalized treatments for patients."

ProOnc TumorSource Dx identifies the tissue-of-origin of a metastatic tumor. The test identifies 25 different tumor types, including colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, and measures the expression level of 48 microRNA biomarkers. ProOnc TumorSource Dx uses a proprietary classifier to assign a primary site to the cancer sample based on the microRNA expression in the tumor and may become a critical tool in the detection of cancer of unknown primary (CUP).

ProOnc Squamous Dx classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers. The test measures the expression level of a squamous microRNA biomarker to differentiate patients that have squamous cell carcinoma of the lung from patients that have non-squamous non-small cell lung cancer.

ProOnc Mesothelioma Dx is a cutting-edge molecular diagnostic test that uses microRNA to differentiate malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.

"MicroRNAs are small, non-coding sequences of RNA that are critically important in many biological and pathological processes," said Harvey Pass, M.D., Professor of Cardiothoracic Surgery and Director of the Division of Thoracic Surgery and Thoracic Oncology at New York University Langone Medical Center and its NYU Cancer Institute. "The sensitivity and specificity of microRNA-based diagnostics should enable clinicians to differentiate particular cancer tissues with increased confidence, which may ultimately guide medical oncologists to deliver the safest and most efficacious therapy for their patients."

For more information about ProOnc Dx tests, please call (877) 378-4919 or visit

Prometheus acquired exclusive U.S. rights to ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx from Rosetta Genomics (Nasdaq: ROSG) in April 2009. The tests are offered as miRview mets, miRview squamous and miRview meso outside of the U.S. In addition, Prometheus and Rosetta are collaborating to develop two new microRNA-based gastroenterology tests.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.

ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx are trademarks of Prometheus Laboratories Inc. miRview mets, miRview squamous and miRview meso are trademarks of Rosetta Genomics Ltd.

SOURCE Prometheus Laboratories Inc.

SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
4. Frutarom Launches New Global Branding
5. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
6. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution
9. AMICAS Launches Major New Version of Radiology Information System at RBMA 2009
10. PARI Respiratory Launches PEP S
11. CVS Caremark Launches Distribution of $3 million in Free Seasonal Flu Shot Vouchers to the Unemployed
Post Your Comments:
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest ... . , Millions of individuals in the United States and Canada wear eyeglasses. Once ... to both correct vision and make a fashion statement. Even celebrities use glasses as ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
Breaking Medicine News(10 mins):